The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Troglitazone Inhibits Atherosclerosis in Apolipoprotein E–Knockout Mice: Pleiotropic Effects on CD36 Expression and HDL
Open accessAbstract
Abstract —Atherosclerotic coronary heart disease is a common complication of the insulin resistance syndrome that can occur with or without diabetes mellitus. Thiazolidinediones (TZDs), which are insulin-sensitizing antidiabetic agents, can modulate the development of atherosclerosis not only by changing the systemic metabolic conditions associated with insulin resistance but also by exerting direct effects on vascular wall cells that express peroxisome proliferator–activated receptor-γ (PPAR-γ), a nuclear receptor for TZDs. Here we show that troglitazone, a TZD, significantly inhibited fatty streak lesion formation in apolipoprotein E–knockout mice fed a high-fat diet (en face aortic surface lesion areas were 6.9±2.5% vs 12.7±4.7%, P <0.05; cross-sectional lesion areas were 191 974±102 911 μm 2 vs 351 738±175 597 μm 2 , P <0.05; n=10). Troglitazone attenuated hyperinsulinemic hyperglycemia and increased high density lipoprotein cholesterol levels. In the aorta, troglitazone markedly increased the mRNA levels of CD36, a scavenger receptor for oxidized low density lipoprotein, presumably by upregulating its expression, at least in part, in the macrophage foam cells. These results indicate that troglitazone potently inhibits fatty streak lesion formation by modulating both metabolic extracellular environments and arterial wall cell functions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Diabetes and Cardiovascular Disease: The Framingham Study
Kannel, W. B. (1979) · JAMA · doi:10.1001/jama.1979.03290450033020 · Cited by 2,936
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
Spontaneous Hypercholesterolemia and Arterial Lesions in Mice Lacking Apolipoprotein E
Zhang, S. H., Reddick, R. L., Piedrahita, J. A., & Maeda, N. (1992) · Science · doi:10.1126/science.1411543 · Cited by 2,237
Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ
Nagy, L., Tontonoz, P., Alvarez, J. G. A., Chen, H., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81574-3 · Cited by 1,860
PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797
High-Density Lipoprotein — The Clinical Implications of Recent Studies
Desforges, J. F., Gordon, D. J., & Rifkind, B. M. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911093211907 · Cited by 1,547
CD36 is a receptor for oxidized low density lipoprotein
Endemann, G., Stanton, L. W., Madden, K. S., Bryant, C. M., White, R. T., & Protter, A. A. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)50272-1 · Cited by 1,281
Schoonjans, K., Peinado‐Onsurbe, J., Lefebvre, A. M., Heyman, R. A., Briggs, M., Deeb, S., Staels, B., & Auwerx, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00918.x · Cited by 1,173
Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans.
Anderson, E. A., Hoffman, R. P., Balon, T. W., Sinkey, C. A., & Mark, A. L. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115260 · Cited by 1,075
Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes
Saltiel, A. R., & Olefsky, J. M. (1996) · Diabetes · doi:10.2337/diab.45.12.1661 · Cited by 1,053
Febbraio, M., Podrez, E. A., Smith, J. D., Hajjar, D. P., Hazen, S. L., Hoff, H. F., Sharma, K., & Silverstein, R. L. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9259 · Cited by 1,044
Improvement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with Troglitazone
Nolan, J. J., Ludvik, B., Beerdsen, P., Joyce, M., & Olefsky, J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411033311803 · Cited by 926
Diabetes and Cardiovascular Disease: The “Common Soil” Hypothesis
Stern, M. P. (1995) · Diabetes · doi:10.2337/diab.44.4.369 · Cited by 739
Ricote, M., Huang, J., Fajas, L., Li, A., Welch, J., Najib, J., Witztum, J. L., Auwerx, J., Palinski, W., & Glass, C. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7614 · Cited by 721
Insulin and Atheroma: 20-Yr Perspective
Stout, R. W. (1990) · Diabetes Care · doi:10.2337/diacare.13.6.631 · Cited by 571
Pasceri, V., Wu, H. D., Willerson, J. T., & Yeh, E. T. H. (2000) · Circulation · doi:10.1161/01.cir.101.3.235 · Cited by 504
Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia.
Law, R. E., Meehan, W. P., Xi, X. P., Graf, K., Wuthrich, D. A., Coats, W., Faxon, D., & Hsueh, W. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118991 · Cited by 476
Fujiwara, T., Yoshioka, S., Yoshioka, T., Ushiyama, I., & Horikoshi, H. (1988) · Diabetes · doi:10.2337/diab.37.11.1549 · Cited by 473
Fruchart, J.-C., Duriez, P., & Staels, B. (1999) · Current Opinion in Lipidology · doi:10.1097/00041433-199906000-00007 · Cited by 425
Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice.
Pászty, C., Maeda, N., Verstuyft, J., & Rubin, E. M. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117412 · Cited by 374
Jackson, S. M., Parhami, F., Xi, X.-P., Berliner, J. A., Hsueh, W. A., Law, R. E., & Demer, L. L. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.9.2094 · Cited by 373
Nozaki, S., Kashiwagi, H., Yamashita, S., Nakagawa, T., Kostner, B., Tomiyama, Y., Nakata, A., Ishigami, M., Miyagawa, J., & Kameda-Takemura, K. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118231 · Cited by 340
Feng, J., Han, J., Pearce, S. F. A., Silverstein, R. L., Gotto, A. M., Hajjar, D. P., & Nicholson, A. C. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32377-4 · Cited by 241
Abe, H., Yamada, N., Kamata, K., Kuwaki, T., Shimada, M., Osuga, J., Shionoiri, F., Yahagi, N., Kadowaki, T., Tamemoto, H., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1594 · Cited by 229
Self-citationMetabolic effects of troglitazone on fructose-induced insulin resistance in the rat
Lee, M. K., Miles, P. D., Khoursheed, M., Gao, K. M., Moossa, A. R., & Olefsky, J. M. (1994) · Diabetes · doi:10.2337/diabetes.43.12.1435 · Cited by 194
Nakata, A., Nakagawa, Y., Nishida, M., Nozaki, S., Miyagawa, J.-I., Nakagawa, T., Tamura, R., Matsumoto, K., Kameda-Takemura, K., Yamashita, S., et al. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.5.1333 · Cited by 179
Antihypertensive effects of CS-045 treatment in obese Zucker rats
Yoshioka, S., Nishino, H., Shiraki, T., Ikeda, K., Koike, H., Okuno, A., Wada, M., Fujiwara, T., & Horikoshi, H. (1993) · Metabolism · doi:10.1016/0026-0495(93)90175-n · Cited by 153
Lefebvre, A., Peinado‐Onsurbe, J., Leitersdorf, I., Briggs, M. R., Paterniti, J. R., Fruchart, J., Fiévet, C., Auwerx, J. H., & Staels, B. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.9.1756 · Cited by 143
Metabolic Effects of Troglitazone on Fructose-Induced Insulin Resistance in the Rat
Lee, M.-K., Miles, P. D. G., Khoursheed, M., Gao, K., Moossa, A. R., & Olefsky, J. M. (1994) · Diabetes · doi:10.2337/diab.43.12.1435 · Cited by 141
Insulin Directly Reduces Platelet Sensitivity to Aggregating Agents: Studies In Vitro and In Vivo
Trovati, M., Anfossi, G., Cavalot, F. L., Massucco, P., Mularoni, E., & Emanuelli, G. (1988) · Diabetes · doi:10.2337/diab.37.6.780 · Cited by 125
Regulation of apo A-I gene expression by fibrates
Staels, B., & Auwerx, J. H. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(97)00313-4 · Cited by 124
Overexpressed lipoprotein lipase protects against atherosclerosis in apolipoprotein E knockout mice
Yagyu, H., Ishibashi, S., Chen, Z., Osuga, J.-I., Okazaki, M., Perrey, S., Kitamine, T., Shimada, M., Ohashi, K., Harada, K., et al. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33414-3 · Cited by 120
Self-citationWhy is insulin not a risk factor for coronary heart disease?
Jarrett, R. J. (1994) · Diabetologia · doi:10.1007/bf00400952 · Cited by 84
Inhibition of oxidation of low density lipoprotein by troglitazone
Noguchi, N., Sakai, H., Katō, Y., Tsuchiya, J., Yamamoto, Y., Niki, E., Horikoshi, H., & Kodama, T. (1996) · Atherosclerosis · doi:10.1016/0021-9150(96)05811-x · Cited by 72
Shinohara, E., Kihara, S., Ouchi, N., Funahashi, T., Nakamura, T., Yamashita, S., Kameda-Takemura, K., & Matsuzawa, Y. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(97)00220-7 · Cited by 67
Vascular Biology of CD36: Roles of this New Adhesion Molecule Family in Different Disease States
Daviet, L., & McGregor, J. L. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1657502 · Cited by 67
Cited by
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors
Michalik, L., Auwerx, J., Berger, J. P., Chatterjee, V. K., Glass, C. K., Gonzalez, F. J., Grimaldi, P. A., Kadowaki, T., Lazar, M. A., O’Rahilly, S., et al. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.5 · Cited by 1,000
Minireview: Lipid Metabolism, Metabolic Diseases, and Peroxisome Proliferator-Activated Receptors
Lee, C.-H., Olson, P., & Evans, R. M. (2003) · Endocrinology · doi:10.1210/en.2003-0288 · Cited by 890
Minireview: Adiposity, Inflammation, and Atherogenesis
Lyon, C. J., Law, R. E., & Hsueh, W. A. (2003) · Endocrinology · doi:10.1210/en.2003-0285 · Cited by 761
PPARs: therapeutic targets for metabolic disease
Berger, J. P., Akiyama, T. E., & Meinke, P. T. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.03.003 · Cited by 713
Metadata
- Authors
- Chen, Z., Ishibashi, S., Perrey, S., Osuga, J.-I., Gotoda, T., Kitamine, T., Tamura, Y., Okazaki, H., Yahagi, N., Iizuka, Y., Shionoiri, F., Ohashi, K., Harada, K., Shimano, H., Nagai, R., & Yamada, N.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2001-03
- Volume
- 21
- Issue
- 3
- Pages
- 372-377
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2086040049
- Cited by
- 320
- References
- 39
- FWCI
- 12.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.